TEThomas Eschenhagen

Thomas Eschenhagen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Eschenhagen has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • F Münzel

    Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

    2 shared publications
  • H. Reichenspurner

    Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany

    2 shared publications
  • S. Pecha

    Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany

    2 shared publications
  • Y. Yildirim

    Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany

    2 shared publications
  • Astrid Weiβmüller

    Institute of Pharmacology and Toxicology University Hospital Hamburg Germany

    1 shared publication
  • B. Karikkineth

    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    1 shared publication

Latest Publications

  • Development of Recipient-Matched Engineered Heart Tissue Using 3D Printing

    by Y. Yildirim, S. Pecha, H. Naito, B. Karikkineth, W. Zimmermann, H. Reichenspurner, T. Eschenhagen


  • Development of recipient-matched engineered heart tissue using 3D printing

    by Y. Yildirim, S. Pecha, S. Hakmi, Y. Alassar, W.H. Zimmermann, T. Eschenhagen, H. Reichenspurner

    Objectives: Engineered pouch-like heart muscle constructs can be applied as heart-embracing cardiac grafts in vivo and might be used as biological ventricular assist devices (BioVAD®). Implantation studies showed micro-gaps between the graft and native heart due to a shape mismatch. The incoherence can lead to electrical coupling problems and loss of support force. Here we developed a procedure to create BioVADs individually matched to the recipient heart. Methods and Results: In group A, small animal magnetic resonance imaging (MRI) heart scan was performed in female wistar rats (n = 10). 3D reconstruction of enddiastolic MRI data was performed and used to create a three-dimensional model of the heart by 3D printing. We used the recipient-matched 3D heart model and grew BioVADs from neonatal rat heart cells, fibrinogen and serum-containing culture medium. In group B, instead of the 3D heart model, a spheric glas spacer (diameter 10 mm) was used to construct pouch like BioVADs. The engineered tissue beat spontaneously and showed contractile properties of native heart muscle including positive inotropic responses to calcium and isoprenaline. In group A recipient heart matched BioVADs were implanted into the corresponding healthy rats (n = 10), while in group B the spheric BioVADs were implanted (n = 10). 14 days after implantation hearts were explanted for histology. Histological analysis of recipient-matched BioVADs showed excellent coverage of the epicardial heart surface, while spheric BioVADs showed high number of micro and macro gaps. Furthermore direct alignment of the BioVADs and recipients hearts was measured in cross-sectioned histological compounds. In group B, a statistically higher number of areas with loss of contact between BioVADs and recipient hearts was seen compared to group A (67% vs 38%; p < 0.001) Conclusion: We developed a novel casting technology using small animal MRI and 3D printing to generate artificial cardiac tissue that is perfectly matched to the recipient heart and exhibits structural and functional properties of native myocardium.

  • Regenerative cellular therapy: Positive remodeling after myocardial infarction using iv injected mesenchymal stem cells and cytokine enhancement

    by T Deuse, C Peter, H Reichenspurner, Wh Zimmermann, T Eschenhagen, R Robbins, S Schrepfer

    Introduction: Adult mesenchymal stem cell (MSC)-based treatment strategies have been proposed to alleviate the consequences of myocardial infarction (MI). Methods and results: Mice underwent LAD ligation. Cytokine enhancement (CE) of HGF or VEGF by intramyocardial injection at the time of MI significantly facilitated MSC homing (11±4 and 7±4, respectively, vs. 1±0.5 cells/HPF without CE; p=0.001). Cardiac geometry and function was monitored over 6 months using ECG-triggered Micro-CTs. The progressive decrease in EF over time (to 19±1%) could be attenuated by CE with HGF (29±6%; p=0.003) or VEGF (28±4%; p=0.004) and subsequent MSC-injection. However, LVEFs of animals treated with CE with HGF or VEGF only, but received no MSC-injection, were similar to those groups that also received IV MSCs (p=0.127 and p=0.54, respectively). Best results were finally achieved by prolonged presence of HGF or VEGF, achieved by intramyocardial injection of MSCs stably transfected to produce HGF or VEGF and firefly luciferase into the infarct border zone. Duration of cytokine release was estimated by monitoring MSC survival using in vivo bioluminescence imaging (BLI). BLI signals were detectable for 10 days in contrast to the rapid fate of the cytokines after single dose administration in the CE group, resulting in preserved LVEFs at 6 months to 33.2±2% and 34.4±7%, respectively. Differentation of MSCs into cardiomyocyte-like cells was not observed. Conclusion: This study highlights the beneficial effect of HGF and VEGF to attenuate the negative LV remodelling after MI and diminishes the role of the MSCs to a pure delivery system for paracrine effects.

  • Functional and electrical integration of engineered heart tissue in a native rat heart

    by S Dhein, I Melnychenko, W Zimmermann, T Eschenhagen, Fw Mohr

    Objectives: Due to a considerable shortage in donor hearts for transplantation facing an increasing number of possible recipients, there is an urgent need for the development of alternative techniques such as engineering of artificial heart tissue. This requires, however, that the engineered heart tissue (EHT) can integrate into native heart. The most sensitive factor is electrical communication and regular propagation of an action potential between EHT and native tissue. Methods: We tested, whether EHT, produced from neonatal rats, implanted for 4 weeks into a rat with a 2 weeks myocardial infarction (LAD-occlusion), allows normal action potential propagation, using a 256 channel potential mapping system allowing to monitor epicardial potentials synchronously at 256 ventricular sites. Results: Infarction led to conduction delay in the occluded area (15±3 (infarcted) vs. 5±1 ms (non-ischemic, n=6). In EHT-treated-infarcted hearts we found a homogenous activation wavefront without significant delay (5.5±1 ms, EHT+infarct). Delivery of rectangular pulses to the EHT led a propagated response from EHT to native heart. Longitudinal and transverse conduction velocity was similar in EHT as in native tissue and anisotropy (=VL/VT) was nearly identical (normal: 4.07±0.91; EHT: 4.15±0.8). Gap junctional uncoupling of the hearts by lowering pH (from 7.36 to 6.7) led to uncoupling between EHT and native heart showing that they were previously well coupled. Fibroblast EHT (sham EHT) did not exhibit any active response. Conclusion: EHT can integrate into native heart tissue and bidirectional communication between EHT and native tissue is possible with biophysical properties very similar to native heart. Thus, EHT opens a new interesting alternative technology.

  • Open Access

    Overexpression of wild‐type Gαi‐2 suppresses β‐adrenergic signaling in cardiac myocytes

    by Thomas Rau, Monika Nose, Ute Remmers, Joachim Weil, Astrid Weiβmüller, Kerry Davia, Sian Harding, Karsten Peppel, Walter J. Koch, Thomas Eschenhagen

    The role of Gαi‐2 overexpression in desensitization of β‐adrenergic signaling in heart failure is controversial. An adenovirus‐based approach was used to investigate whether overexpression of Gαi‐2 impairs β‐adrenergic stimulation of adenylyl cyclase (AC) activity and cAMP levels in neonatal rat cardiac myocytes (NRCM) and cell shortening of adult rat ventricular myocytes (ARVM). Infection of NRCM with Ad5Gαi‐2 increased Gαi‐2 by 50–600% in a virus dose‐dependent manner. Overexpression was paralleled by suppression of GTP‐ and isoprenaline‐stimulated AC by 10–72% ( P P P <0.02), respectively. β1‐ and β2‐adrenergic stimulation was reduced similarly. Our results suggest that (a) the Gαi‐2 system exhibits tonic inhibition of stimulated AC in cardiac myocytes, (b) Gαi‐2‐mediated inhibition is concentration‐dependent and occurs at Gαi‐2 levels seen in heart failure, and (c) Gαi‐2‐mediated inhibition affects both β1‐ and β2‐adrenergic stimulation of AC. The data argue for an important, independent role of the Gαi‐2 increase in heart failure.


  • Montelukast

    by F Münzel, U Mühlhäuser, T Eschenhagen

    Montelukast (Singulair®, Abb. [ 1 ]) wurde als erster und bislang einziger Vertreter der Leukotrienrezeptorantagonisten im Jahr 1998 in Deutschland zugelassen. Mit dieser Substanzklasse steht ein neues Wirkprinzip für die Therapie des Asthma bronchiale zur Verfügung.

  • Top Cited Papers

    Tissue Engineering of a Differentiated Cardiac Muscle Construct

    by W.-H. Zimmermann, K. Schneiderbanger, P. Schubert, M. Didié, F. MünZel, J.F. Heubach, S. Kostin, W.L. Neuhuber, T. Eschenhagen

    Cardiac tissue engineering is an emerging field. The suitability of engineered heart tissue (EHT) for both in vitro and in vivo applications will depend on the degree of syncytoid tissue formation and cardiac myocyte differentiation in vitro, contractile function, and electrophysiological properties. Here, we demonstrate that cardiac myocytes from neonatal rats, when mixed with collagen I and matrix factors, cast in circular molds, and subjected to phasic mechanical stretch, reconstitute ring-shaped EHTs that display important hallmarks of differentiated myocardium. Comparative histological analysis of EHTs with native heart tissue from newborn, 6-day-old, and adult rats revealed that cardiac cells in EHTs reconstitute intensively interconnected, longitudinally oriented, cardiac muscle bundles with morphological features resembling adult rather than immature native tissue. Confocal and electron microscopy demonstrated characteristic features of native differentiated myocardium; some of these features are absent in myocytes from newborn rats: (1) highly organized sarcomeres in registry; (2) adherens junctions, gap junctions, and desmosomes; (3) a well-developed T-tubular system and dyad formation with the sarcoplasmic reticulum; and (4) a basement membrane surrounding cardiac myocytes. Accordingly, EHTs displayed contractile characteristics of native myocardium with a high ratio of twitch (0.4 to 0.8 mN) to resting tension (0.1 to 0.3 mN) and a strong β-adrenergic inotropic response. Action potential recordings demonstrated stable resting membrane potentials of −66 to −78 mV, fast upstroke kinetics, and a prominent plateau phase. The data indicate that EHTs represent highly differentiated cardiac tissue constructs, making EHTs a promising material for in vitro studies of cardiac function and tissue replacement therapy.


    • 1 November 2001
      • Vol. 143  (44) , 44-7

    [Emergencies in the practice. Hazards of "mix syringe"].

    by F Münzel, T Eschenhagen, T Rau, O Zolk

    • 2 November 2000
      • Vol. 142  (44) , 28-33

    [Overview of drug interactions. Combining drugs correctly!].

    by T Eschenhagen

    Drug interactions may be of two basic types: pharmacodynamic and pharmacokinetic. Pharmacodynamic interactions may be direct, in that two drugs intervene synergistically or antagonistically in the same biological system, or indirect, meaning that one drug may modify a parameter of central importance to a system, which in turn may influence the activity of the second drug. Of the two possibilities pharmacokinetic interactions are the more difficult to recognize since they have nothing to do with the biological action proper. Here, the absorption and metabolism of the drug are the most important factors. A compounding factor is the fact that the activity of a drug may show marked individual, genetically determined, differences.